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ABSTRACT
Objectives: Lead antituberculosis (anti-TB) molecules
with novel mechanisms of action are urgently required
to fuel the anti-TB drug discovery pipeline. The aim of
this study was to validate the use of the high-
throughput spot culture growth inhibition (HT-SPOTi)
assay for screening libraries of compounds against
Mycobacterium tuberculosis and to study the inhibitory
effect of ibuprofen (IBP) and the other 2-arylpropanoic
acids on the growth inhibition of M tuberculosis and
other mycobacterial species.
Methods: The HT-SPOTi method was validated not
only with known drugs but also with a library of 47
confirmed anti-TB active compounds published in
the ChEMBL database. Three over-the-counter
non-steroidal anti-inflammatory drugs were also
included in the screening. The 2-arylpropanoic acids,
including IBP, were comprehensively evaluated
against phenotypically and physiologically different
strains of mycobacteria, and their cytotoxicity was
determined against murine RAW264.7 macrophages.
Furthermore, a comparative bioinformatic
analysis was employed to propose a potential
mycobacterial target.
Results: IBP showed antitubercular properties while
carprofen was the most potent among the
2-arylpropanoic class. A 3,5-dinitro-IBP derivative was
found to be more potent than IBP but equally selective.
Other synthetic derivatives of IBP were less active, and
the free carboxylic acid of IBP seems to be essential
for its anti-TB activity. IBP, carprofen and the 3,5-
dinitro-IBP derivative exhibited activity against
multidrug-resistant isolates and stationary phase bacilli.
On the basis of the human targets of the 2-
arylpropanoic analgesics, the protein initiation factor
infB (Rv2839c) of M tuberculosis was proposed as a
potential molecular target.
Conclusions: The HT-SPOTi method can be employed
reliably and reproducibly to screen the antimicrobial
potency of different compounds. IBP demonstrated
specific antitubercular activity, while carprofen was the
most selective agent among the 2-arylpropanoic class.
Activity against stationary phase bacilli and multidrug-
resistant isolates permits us to speculate a novel
mechanism of antimycobacterial action. Further
medicinal chemistry and target elucidation studies
could potentially lead to new therapies against TB.
ARTICLE SUMMARY
Article focus
▪ Lead antituberculosis (anti-TB) molecules with
novel mechanisms of action are urgently required
to fuel the anti-TB drug discovery pipeline.
▪ Whole-cell phenotypic screening has been
employed to discover currently used therapeutic
antibiotics, and it is still considered a crucial bio-
assay in the discovery of new antimicrobials for
tackling global health challenges such as TB.
▪ Repurposing old drugs has emerged as a novel
paradigm to develop drugs against infectious
diseases particularly of the developing world, as
it allows saving of time and resources during
drug development. These molecules have an
established safety profile, which has been docu-
mented through their exposure to a large and
often diverse population.
Key messages
▪ We found that ibuprofen (IBP) and carprofen,
two non-steroidal anti-inflammatory drugs cur-
rently used as pain relievers in humans and
animals, respectively, displayed specific growth
inhibitory properties against the Mycobacterium
tuberculosis complex.
▪ Evaluation of different synthetic derivatives of
IBP demonstrated that the free carboxylic acid
was required for anti-TB activity.
▪ IBP, carprofen and a synthetic derivative of IBP,
namely 3,5-dinitro-IBP, showed inhibitory activity
against multidrug-resistant M tuberculosis
clinical isolates and the stationary-phase
Mycobacterium bovis BCG in the same concen-
tration range as exponential-phase susceptible M
tuberculosis H37Rv.
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BACKGROUND
The global emergence of multidrug and extensively
drug-resistant Mycobacterium tuberculosis (M/XDR-TB)1
strains poses a major threat to our ability to control
tuberculosis (TB). There is an urgent need for lead
candidates with novel mechanisms of action to fuel the
current anti-TB drug discovery pipeline; however,
the numerous target-based approaches originating from
the boom of postgenomic research have unfortunately
failed to deliver bioactive molecules for future develop-
ment. Whole-cell phenotypic screening has been the
method of choice for discovering most of the thera-
peutic antibiotics used today and it is still considered a
crucial bioassay in the discovery of new antimicrobials
for tackling global health challenges such as TB. The
principal reason for this is that whole-cell screening
interrogates all the biochemical targets simultaneously
in a speciﬁc physiological context, a process more efﬁ-
cient than focusing on one target that may have no bio-
logical relevance. All the current antitubercular drugs in
clinical development, such as OPC-67683 (delamanid),
PA-824, TMC207 (bedaquiline), PNU-100480 (sutezolid)
and SQ109, were discovered as a result of whole-cell
screening while not a single novel anti-TB lead has yet
emerged from target-based screening.2
The agar plate proportion method estimates the
number of colony forming units (CFU). It is considered
the gold standard in whole-cell screening assays and
serves to determine the minimum inhibitory concentra-
tion (MIC) of a particular drug or inhibitor. Although
the method is convenient, it tests the effect of a drug
against a single viable cell rather than a mixed popula-
tion of cells, which is more realistic to the host-infection
setting. The agar proportion method is not, however,
designed to handle a large number of samples. It
requires considerable amounts of the inhibitor and can
take more than a month for the antitubercular proper-
ties of a compound to be determined. A lower volume
agar-based assay was initially introduced in 2004 by
Bhakta et al3 for assessing the susceptibility of
Mycobacterium bovis BCG wild-type and its mutants to
isoniazid (INH). The spot culture growth inhibition
(SPOTi) assay method has been enhanced in various
studies using 6-well, 24-well and 48-well plates for screen-
ing growth inhibitors against mycobacteria.4–7 Of imme-
diate importance, the methodology has also been
independently employed for drug susceptibility testing
(DST) of clinical isolates in a TB reference laboratory in
the Netherlands.8
There is currently a renewed interest in re-purposing
old drugs especially for treating infectious diseases,9
saving time, effort and expenses from a new drug devel-
opment because of the existing knowledge of their
pharmacological (PK/PD) proﬁles, toxicity and safety.10
For example, the neuroleptic drug thioridazine was
successfully used for treating M/XDR-TB patients in
2010, and clinical trials are currently in progress.11 12
Disulﬁram, which was initially developed for treating
alcoholism, has received attention because of its potent
activity against drug-resistant TB strains, raising the possi-
bility of its clinical use as a repurposed anti-TB agent.13
Furthermore, a study published parallel to our investiga-
tion found that the non-steroidal anti-inﬂammatory drug
(NSAID) oxyphenbutazone was cidal to the non-
replicative M tuberculosis bacilli.14 Other off-patent drugs
(or attrition candidates) may still be waiting on the
chemical shelf for their anti-infective power to be discov-
ered. These entities might also help to unlock previously
neglected molecular targets against global infective
health challenges.
In this work, the miniaturisation of the SPOTi assay to
a 96-well format is described for the ﬁrst time, focusing
on its application to a laboratory-based screening of
drugs and inhibitor libraries against an array of bacterial
pathogens and discussing its advantages over conven-
tional methods. The validation of the high-throughput
SPOTi (HT-SPOTi) was carried out with antimicrobial
drugs and inhibitors. Common over-the-counter (OTC)
analgesics were screened, and surprisingly, ibuprofen
(IBP) was found to display growth inhibitory properties
against M tuberculosis growth in vitro. Previous reports
have found that IBP can inhibit the growth of not only
dermatophytic fungi,15 but also Gram-positive bacteria at
acidic pH.16 Against M tuberculosis, IBP was, however,
found to be unable to decrease bacterial loads in the
lung or spleen when administered at doses of 10, 20 or
40 mg/kg in a murine infection model. More import-
antly, the sterilising activity of pyrazinamide (PZA)
increased signiﬁcantly when administered concomitantly
with IBP or aspirin at 20 mg/kg.17 In this work, a com-
prehensive spectrum of activity study was performed by
evaluating members of the 2-arylpropanoic class against
a different array of bacterial species. Synthetic chemical
modiﬁcations of IBP were also made in order to attempt
to elucidate any key structural requirements for activity.
This ﬁrst report tries to underline the anti-TB potential
of the 2-arylpropanoic class, raising further interest in
their medicinal chemistry and the study of their mech-
anism(s) of action as speciﬁc antitubercular agents.
ARTICLE SUMMARY
Strengths and limitations of this study
▪ We have established the feasibility of screening libraries of
compounds against different microbial species using the high-
throughput spot culture growth inhibition assay.
▪ We have demonstrated that the 2-arylpropanoic acids have
specific growth inhibitory effects against members of the M
tuberculosis complex.
▪ Our study was limited in the screening of different physio-
logical states of M tuberculosis and it remains to be confirmed
whether these compounds have activity against non-replicative
populations or not.
▪ Future work will include the precise determination of the
anti-TB mechanism of action of these compounds.
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METHODS
Small molecules
All commercially available drugs used in this study were
purchased from Sigma and dissolved in either cell
biology-grade dimethyl sulfoxide (DMSO) or sterile
deionised water. A collection of 47 compounds was pur-
chased following shortlisting procedures applied to com-
pounds identiﬁed as TB actives in publicly available
phenotypic screening data. Pipeline Pilot (Accelrys
Software Inc) was used to process this data, ﬁrst, by com-
bining data from ChEMBL (http://www.ebi.ac.uk/
chembl/) and PubChem (pubchem.ncbi.nlm.nih.gov),
identifying 6625 unique compounds with an MIC
≤100 μM. Of these,1283 compounds with any of the fol-
lowing undesirable physicochemical properties were
removed: molecular weight greater than 600, more than
six rings, the presence of rings larger than seven atoms,
more than six H-bond donors, more than 12 H-bond
acceptors, more than 11 freely rotatable non-terminal
bonds, more than seven non-contiguous rotatable
bonds, the presence of atoms other than C, H, N, O, P,
S or halogens, more than two charged atoms, a net
formal charge of more than +1 or less than –1, and
ﬁnally a cLogD of more than 6 or less than –1. A further
334 compounds with undesirable substructures, deﬁned
as SMARTS by Pearce,18 were removed. Additional cri-
teria including predicted solubility, structural diversity
and commercial availability were considered when
manually shortlisting the 47 compounds that were even-
tually purchased and screened using the 96-well SPOTi
assay.
Bacteria
The bacterial strains used in this study were M tuberculosis
H37Rv (ATCC27294), M bovis BCG (ATCC35734),M aurum
(ATCC23366), M neoaurum (ATCC25795), M smegmatis
mc2155 (ATCC700084) Staphylococcus aureus (ATCC25923),
S aureus strain (EMRSA-16), a clinical isolate kindly
donated by Dr Paul Stapleton, Pseudomonas putida
(ATCC12633) and Escherichia coli DH5α (ATCC53868).
Rhodococcus equi RHA1 was a generous gift from Professor
Edith Sim. The MDRM tuberculosis strains used in this study
were clinical isolates collected from the Royal Free
Hospital, National Health Sevice Trust, London. Strain 11 :
139 was resistant to ethambutol (EMB), INH and rifampin
(RIF), strain 11 : 169 was resistant to all ﬁrst-line drugs and
11 : 368 was resistant to INH, RIF and streptomycin (STR).
Middlebrook 7H9 broth supplemented with 10% oleic
acid, albumin, dextrose and catalase (OADC) was used
for the growth of M tuberculosis H37Rv. Middlebrook 7H9
broth supplemented with 0.02% (v/v) glycerol, 0.05%
(v/v) tween-80 and 10% (v/v) albumin, dextrose and
catalase was used for the growth of M bovis BCG and M
aurum. S aureus strains and P putida were grown in nutri-
ent broth and E coli in Luria-Bertani (LB) broth. All cul-
tures were initiated from a cryopreserved glycerol stock,
passaged twice for growth uniformity and grown until
the mid-exponential phase at 37°C (actively dividing
stage of bacterial growth) prior to the SPOTi assay. M
bovis BCG was grown in a rolling bottle at 2 rpm using a
100 mL volume of supplemented liquid media. M tuber-
culosis H37Rv was grown as a standing culture in 10 mL
supplemented liquid media. M aurum, S aureus strains
and E coli were grown at 180 rpm as shaking cultures in
10 mL of liquid media. R equi RHA1 was grown in nutri-
ent broth at 30°C with 180 rpm shaking. A late
stationary-phase M bovis BCG culture was prepared by
culturing exactly in the conditions described by tightly
closing the lid of the rolling bottle, and incubating for
100 days before the assay.
Drug susceptibility
The drugs used in this study were dissolved at a ﬁnal
concentration of 50 g/L. Serial dilution was performed
in a sterile, thin 96-well frosted subskirted microtitre
plate that acted as a master plate. A column containing
only DMSO was also included. Two microlitres of each
of the diluted compounds were then transferred into
sterile 96-well plates. The plates were ﬁlled up to 200 µL
with agar-based media. Middlebrook 7H10 supplemen-
ted with 0.5% (v/v) glycerol and 10% (v/v) OADC was
used for mycobacterial species. Nutrient agar media
were used for S aureus, P putida and R equi RHA1 strains,
whereas LB agar was used for E coli. The agar-based
media were prevented from solidifying by using a hot
plate at 50°C with constant stirring. The distribution of
the agar media into the 96 wells was achieved using the
MultidropCombi microplate dispenser (Thermo-Fisher
Scientiﬁc). Plates were dried and a diluted inoculum of
bacteria was applied (2 µL of ∼105 CFU/mL) into each
well by either the use of a single pipettor or by using the
MultidropCombi. Plates were subsequently incubated at
37°C overnight (16 h) for S aureus strains, P putida and E
coli, 5 days for M aurum and 2 weeks for M bovis BCG
and M tuberculosis strains. Plates were incubated at 30°C
overnight (16 h) for R equi RHA1. The plates were then
observed and MIC values were determined as the lowest
concentration of the drug where no bacterial growth was
observed.
The antibiotic susceptibility in acidic stress was
observed according to a previously described method.19
M neoaurum (OD∼1.0) cells were washed with
phosphate-buffered saline pH 7.0 twice before being
stressed by placing in an acidic environment of Sauton’s
liquid medium pH 5.8 or 7.0 for 1 h at 37°C. Stressed
cells (2 µL of 106 cells/mL) were spotted onto 24-well
plates containing Sauton’s agar medium at pH 5.8 and
7.0 with antibiotic concentrations ranging from 0, 20,
30, 40, 50, 60, 65, 70, 80, 90, 100 to 200 mg/L.
The late stationary phase cells were obtained in a
rolling bottle by tightly closing the lid of an M bovis BCG
culture in 100 mL of supplemented Middlebrook 7H9.
The lid remained tightly closed for 100 days and then
the SPOTi experiment was performed on 24-well plates
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with supplemented Middlebrook 7H10, using four dif-
ferent dilutions of the 100-day-old bacterial culture
(neat, 10−1, 10−2 and 10−3).
Growth curves and CFU counting
The growth curves were determined by measuring
optical density at 600 nm (OD600) of M bovis BCG cul-
tures grown in 100 mL of supplemented Middlebrook
7H9, every day for 2 weeks. The concentrations of inhibi-
tors used were 90 (1×MIC) and 180 mg/L (2×MIC) for
IBP, 65 (1×MIC) and 130 mg/L (2×MIC) for carprofen
and 50 (1×MIC) and 100 mg/L (2×MIC) for
3,5-dinitro-IBP. One experiment was performed by
adding the inhibitors before inoculation, while another
experiment was performed by adding the inhibitors at
the early-exponential phase of bacterial growth when
the OD600 of the control was 0.6. CFU were measured by
spreading (in triplicate) 100 µL of different dilutions
(10−4, 10−5, 10−6, 10−7, 10−8) of the bacterial cultures in
Petri dishes containing 25 mL of supplemented
Middlebrook 7H10. The Petri dishes were incubated at
37°C for 3 weeks and the number of colonies was
counted. For the ﬁrst experiment, when the inhibitors
were added before inoculation, the CFU of all samples
were analysed when the OD600 of the control was 0.8.
For the early-exponential phase experiment, CFU was
determined for all samples 24 h after the addition of the
inhibitors.
Synergism
The synergistic effect of IBP, carprofen and 3,5-dinitro-
IBP was examined in combination with INH, EMB and
RIF against M tuberculosis H37Rv. The assay was conducted
in a 48-well microtitre plate using a SPOTi checkerboard
distribution. The compounds were serially diluted in
DMSO to include MIC and sub-MIC concentrations.
Each row of the 48-well plate contained different concen-
trations of the IBP derivatives and each column con-
tained different concentrations of the ﬁrst-line drug. The
checkerboard was constructed by adding 1 µL of each of
the stock concentrations to the corresponding well and
then dispensing 1 mL of warm (55°C) Middlebrook
7H10 agar medium supplemented with 10% (v/v)
OADC using the MultidropCombi Reagent Dispenser
(Thermo-Fisher Scientiﬁc). The plates were then spotted
with M tuberculosis H37Rv as previously described. The
plates were incubated in sealed bags at 37°C for 2 weeks
and Fractional Inhibitory Concentration Indices (FICI)
values were calculated using the following formula:
FICI =
MICA in presence of B
MICA
þMICB in presence of A
MICB
An FICI value ≤0.5 indicated synergism; a value
between 0.5 and 4.0 indicated no interaction; and a
value higher than 4.0 indicated antagonism.
Cytotoxicity and macrophage-infection model
The cytotoxicity assay on mouse macrophage cells (RAW
264.7) was performed according to a method described
previously.19 The intracellular inhibition assay using M
aurum as a surrogate and RAW 264.7 macrophages was
performed as described.19 Brieﬂy, the intracellular inhib-
ition assay was performed by infecting 5×105 macro-
phage cells/well with M aurum in a 10 : 1 multiplicity of
infection for 1 h at 37°C in 24-well plates. The culture
was washed with RPMI-1640 three times and incubated
with different concentrations of the compounds (0, 0.39,
1.5, 6.25, 25 and 100 mg/L) in RPMI-1640 media.
Following incubation for 48 h, the cells were washed
twice with RPMI-1640 and lysed in 500 µL of distilled
water at room temperature for 10 min. The lysed cells
were centrifuged and resuspended into 50 µL of distilled
water, and then 5 µL was spotted onto the 24-well plates
containing Middlebrook 7H10 agar. The plates were
incubated at 37°C for 5 days to determine intracellular
survival.
Protein homology searching using bioinformatics
Using a literature search, the reported molecular targets
of IBP and the other 2-arylpropanoic acids were identi-
ﬁed in humans and their protein amino acid sequences
retrieved from the UniProt protein database (http://
www.uniprot.org). These sequences were then used to
search for the existence of homologous proteins in
mycobacteria and in other bacterial species. The blastp
algorithm at the NCBI BLAST server (http://www.blast.
ncbi.nlm.nih.gov) was employed and an Evalue cut-off of
<0.001 was considered for a protein hit to be signiﬁcant.
Furthermore, the pairwise sequence alignment of the
possible human target with the identiﬁed mycobacterial
homologue was performed using the MAFFT (Multiple
Alignment using Fast Fourier Transform) algorithm at
the EBI web server (http://www.ebi.ac.uk/Tools/msa/
mafft) and the alignment was visualised using ESPript
(espript.ibcp.fr/ESPript/ESPript).
RESULTS
Antibiotic susceptibility using HT-SPOTi
A selection of 18 antibiotics were used, including: the
four ﬁrst-line anti-TB drugs INH, EMB, PZA and RIF; six
second-line anti-TB drugs STR, ethionamide (ETH),
p-aminosalicylic acid (PAS), D-cycloserine (DCS), oﬂoxa-
cin (OFL) and kanamycin (KAN); three β-lactams,
namely cephalosporin C (CEP), ampicillin (AMP) and
penicillin G (PEN); ﬁve broad-spectrum antibiotics phos-
phomycin (PHO), bacitracin (BAC), gentamicin (GEN),
vancomycin (VAN) and metronidazole (MET). Each
antibiotic was tested in the range of 125–0.12 mg/L fol-
lowing a twofold dilution pattern against the virulent M
tuberculosis H37Rv, two surrogate organisms M aurum and
M bovis BCG, a Gram-positive susceptible strain of
S aureus, a clinical methicillin-resistant S aureus isolate
(EMRSA-16) and ﬁnally two Gram-negative bacteria,
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P putida and E coli. The schematic ﬁgure 1A summarises
the experimental protocol and a typical result of the
HT-SPOTi assay explicitly showing the presence or
absence of microbial growth. The MIC values were
recorded as the lowest concentration at which no bacter-
ial growth was observed by the naked eye. All bacterial
species were highly susceptible to STR and OFL, except
for the EMRSA16 S aureus isolate (ﬁgure 1B), whereas
the Mycobacterium species were selectively inhibited by
INH, EMB and PAS. This experiment validated the use
of the HT-SPOTi assay for drug screening purposes as
the results were found to be reproducible when using a
different batch of drugs and microorganisms (greater
than 95% of the determinations had the same MIC).
Validation of the HT-SPOTi assay against a library of
inhibitors
Since one of the main difﬁculties in attaining efﬁcacy
against M tuberculosis is achieving sufﬁcient cell wall per-
meation, a focused set of 47 conﬁrmed active com-
pounds having MIC values ≤100 μM was selected from
the ChEMBL database. The compounds were shortlisted
based on predicted physicochemical properties, sub-
structural ﬁlters and commercial availability (see
Methods section). When tested in the 96-well format
HT-SPOTi assay against M tuberculosis H37Rv, out of 47
compounds, 5 had MIC values above 100 µM, 11 had
MIC values between 100 and 33.3 µM, 22 had MIC
values between 33.3 and 11.1 µM, 6 had MIC values
between 11.1 and 3.7 µM and 3 had MIC values below
3.7 µM. Figure 1C shows the chemical structures of the
four most potent hits together with their reported and
experimental MIC values. All the chemical structures,
ChEMBL IDs and MIC values can be found in the
online supplementary ﬁgure S1.
The MIC values obtained using the 96-well plate
HT-SPOTi method were consistently higher than those
reported in the ChEMBL database (ﬁgure 1D), except
for three compounds with ChEMBL ID 1454848, 233896
and 1418750. This comparison plot showed that most of
the compounds were below the identity line (1 : 1 line),
and three compounds were above the line. It was
Figure 1 High-throughput spot culture growth inhibition (HT-SPOTi) is a reproducible minimum inhibitory concentration (MIC)
determination method. (A) Schematic representation of the HT-SPOTi methodology. (B) Trends in MIC values for a set of
selected antibiotics against various bacterial species using the HT-SPOTi assay. MICs were determined as the complete growth
inhibition (no visible spot) at the depicted concentration. (C) Chemical structures of the four most active ChEMBL hits and
comparison of their MIC values. (D) Correlation plot between reported values and experimental HT-SPOTi MIC values. MIC
values greater than 100 µM were not plotted. (E) MIC distribution histogram of the active ChEMBL focused set.
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interesting to note that ChEMBL 1454848 had a PAS unit
covalently bound to a thiazolecoumarin moiety. Its MIC
value was found to be <20 µM in both assays, conﬁrming
a high potency. The two most active molecules, ChEMBL
1561278 and 11367626, were found to be potent (MIC
3.7 µM) in the 96-well SPOTi assay, while ChEMBL
1352127 and 1575951 were less active (ﬁgure 1C). The
distribution of MIC, according to a different range of
inhibitor concentration, was found to be similar between
the available data and the HT-SPOTi assay (ﬁgure 1E)
IBP and the other 2-arylpropanoic acids are growth
inhibitors of M tuberculosis
The three most widely used OTC analgesics paraceta-
mol, aspirin and IBP were tested for growth inhibition
on M bovis BCG using the SPOTi assay. The results were
MIC values of >500, 250 and 100 mg/L, respectively, on
the initial screen. Although a previous report mentioned
a synergistic effect between IBP and PZA on a murine
model,17 no literature data were found on the in
vitro activity of IBP against mycobacteria. Therefore,
we screened most of the available (Sigma-Aldrich)
2-arylpropanoic drugs such as IBP (1), naproxen (2),
fenoprofen (3), ketoprofen (4), ﬂurbiprofen (5), indo-
profen (6), carprofen (7), loxoprofen (8), and oxapro-
zin (9). Novel synthetic IBP derivatives, IBP methyl ester
(10), IBP cyclopentylamide (11), IBP benzylamide (12),
IBP 4-aminobenzylamide (13), IBP D-glutamic acid
amide (14), 3,5-dinitro-IBP (15) and 3,5-dinitro-IBP
methyl ester (16) were also prepared (ﬁgure 2A) in an
attempt to elucidate structure-activity relationships. The
synthetic procedures and analytical data can be found in
the online supplementary information.
IBP (1) completely inhibited the in vitro growth of M
tuberculosis H37Rv at concentrations >75 mg/L (table 1).
Naproxen, fenoprofen, ketoprofen, ﬂurbiprofen, indo-
profen and oxaprozin were found to be less active with
MIC values >90 mg/L (table 1). Loxoprofen had an
MIC value comparable to that of 1 but was around 700
times more expensive. Carprofen (7) was found to be
more potent than IBP, with an MIC value of 40 mg/L.
Only 4, 6 and 9 were found to be inactive at the highest
concentration tested (MIC >100 mg/L). Similar trends
of activity were observed against the vaccine strain M
bovis BCG and the opportunistic M aurum and M
neoaurum species. Interestingly, lower MIC values were
observed against M neoaurum when tested in acidic
(pH=5.8) compared with neutral (pH=7.0) Sauton’s
agar media.
All the commercial 2-arylpropanoic acids were half-
inhibitory to the RAW264.7 macrophage cells at
1000 mg/L, with the selectivity indices (SI) ﬂuctuating
between values of 10 and 25. Carprofen was the hit with
the widest therapeutic window. When tested in a
macrophage-infected model, most of the 2-arylpropanoic
acids required a higher concentration to produce an
effective killing of intracellular bacteria. Interestingly, 1
and 3 were active on the intracellular milieu with
concentrations equal to or slightly higher than the MIC
values.
The effect of the compounds was also tested against
other microorganisms to assess their speciﬁcity. Neither
M smegmatis nor other acid-fast bacteria, such as R equi
RHA1 or Gram-positive S aureus (susceptible and
EMRSA strains) or Gram-negative E coli JM109 or P
putida, were inhibited at a 100 mg/L concentration of
compounds 1–7. We observed that this class of drugs was
selective against slow-growing mycobacterial organisms,
probably those with the facility to live in an intracellular
environment.
Among the synthetic IBP derivatives, only 12, 13, 15
and 16 showed mycobacterial growth inhibition (table 2).
The methyl ester of IBP (10) was inactive with an MIC
value higher than 100 mg/L, and the cyclopentylamide
(11) was also inactive, indicating that the presence of a
free carboxylic acid appears to play a substantial role in
the antitubercular effect. The benzylamide moiety
present in 12 and 13, although masking the free car-
boxylic acid, accorded activity but at the expense of being
much more cytotoxic towards mammalian cells (SI=2.5).
Another amide derivative of IBP, the dicarboxylic
D-glutamic acid derivative 14, was inactive, a result that
supported the requirement of a free propanoic acid carb-
oxyl group for effective growth inhibition. In conse-
quence, the potential modiﬁcations for improving the
anti-TB activity of 1 were envisaged to be carried out
either on the aromatic ring or on the isobutyl chain. The
3,5-dinitro-IBP derivative (15) was more active than IBP
itself, achieving an MIC value of 30 mg/L against the
virulent H37Rv strain. The compound was shown to be
more cytotoxic than the parent compound 1; however,
the selectivity index was the same. The introduction of a
methyl ester functionality (giving 16) was detrimental to
the anti-TB potential of 15, while substantially increasing
its cytotoxicity.
The three most active 2-arylpropanoic acids, IBP (1),
carprofen (7) and 3,5-dinitro-IBP (15), were screened
against three MDR M tuberculosis clinical isolates. The
MIC values were in the range 20–50 mg/L, comparable
to the inhibitory values observed against the H37Rv
strain (table 3). Furthermore, their synergistic or antag-
onistic actions in combination with the ﬁrst-line anti-TB
drugs INH, EMB and RIF were examined against M
tuberculosis H37Rv using a modiﬁed version of the SPOTi
assay to represent a classic checkerboard assay format.
There was no interaction between the 2-arylpropanoic
acids IBP (1), carprofen (7) and 3,5-dinitro-IBP (15)
and the ﬁrst-line anti-TB drugs (data not shown).
For these three most active 2-arylpropanoic acid inhi-
bitors, a growth curve was measured using the MIC
(1×MIC) and two times the MIC (2×MIC) added to the
liquid Middlebrook 7H9 media at the start of the experi-
ment and in the early exponential phase of the growth
of M bovis BCG. The presence of carprofen (7) in the
liquid Middlebrook 7H9 media at 70 (1×MIC) or
140 mg/L (2×MIC) from the start of the experiment
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completely prevented the growth of M bovis BCG
(ﬁgure 2B), whereas the presence of 3,5-dinitro-IBP
(15) at 1×MIC concentration (50 mg/L) did not show
any effect on the growth and the culture evolved simi-
larly to the DMSO control. The presence of IBP (1) at
1×MIC concentration (75 mg/L) caused a slight delay in
the growth but after a further 24 h of incubation, the
OD values were equal to the DMSO control. However,
when the liquid media contained 2×MIC concentrations
of both 1 and 15, the growth was completely prevented.
Figure 2 Ibuprofen and the related 2-arylpropanoic acids are inhibitors of slow-growing Mycobacterium. (A) Chemical structures
of commercially available compounds 1–9 and synthetically modified-IBP derivatives 10–16. (B) Growth curve of M bovis BCG in
liquid media growing with 1×minimum inhibitory concentration (MIC) and 2×MIC of 1, 7 and 15 added before inoculation (as
shown by the arrow). (C) Growth curve describing the same experiment with addition of the inhibitors at an early-exponential
phase (as shown by the arrow). (D) Colony forming units (CFU) count of M bovis BCG cells treated with 1×MIC and 2×MIC of 1,
7 and 15 added before inoculation. CFU was determined simultaneously for all treatment when the OD600 of the control was 0.8.
(E) CFU count determined simultaneously for all treatments 24 h after the addition of the inhibitors at the early-exponential
phase.
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In contrast, when the inhibitors were added at exactly
the same concentrations in the early exponential phase
of mycobacterial growth (ﬁgure 2C; after 3.5 days of
liquid rolling culture, OD600 ∼ 0.5), 1 and 15 did not
arrest mycobacterial growth. Remarkably, the 2×MIC con-
centration of 7 completely stopped mycobacterial growth;
however, the bacterial numbers did not change, main-
taining a constant OD value throughout the experiment
(even after 1 month of incubation). When 7 was added at
the 1×MIC concentration, the growth rate was signiﬁ-
cantly reduced compared with the DMSO control. A
similar decrease in the growth was observed when 1 was
administered at a concentration of 180 mg/L (2×MIC).
The presence from the start of the experiment of the
2×MIC concentration of carprofen (7) notably affected
bacterial multiplication, achieving a reduction of M bovis
BCG cells of more than 6-log CFU compared with the
DMSO control (ﬁgure 2D). This result demonstrates the
potent prevention of mycobacterial growth by carprofen.
At the 2×MIC concentration, the dinitro derivative 15
reduced the number of cells by more than 3-log CFU,
whereas 1 decreased growth by only 1-log unit. When
the compounds were added at the early exponential
phase of growth, little effect on bacterial viability was
observed after 36 h. There was no decrease in bacterial
CFU even for carprofen at 2×MIC, demonstrating
little killing ability but rather a bacteriostatic effect
(ﬁgure 2D).
MIC values were also dependent on the physiological
condition of the inoculum (table 4). The MIC values of
INH, RIF and EMB against the exponential-phase bacilli
were signiﬁcantly lower compared with the values
against stationary-phase bacteria for all the bacterial
dilutions tested. Interestingly the three most active
2-arylpropanoic acids, IBP (1), carprofen (7) and
3,5-dinitro-IBP (15), had exactly the same MIC values
(80, 40 and 60 mg/L, respectively) against both the late
stationary phase bacilli and the exponential phase bacilli
for the 10−3 bacterial dilution. When a higher number
of bacterial cells was spotted, the similar effect of the
2-arylpropanoic acids against both exponential and sta-
tionary phase cells was less evident, but still observed.
These results suggest that this class could be active
against mycobacterial stages of low metabolic activity
(eg, persistent or dormant cells).
It has been recognised that IBP and the other
2-arylpropanoic acids have multiple human biological
targets, as demonstrated by their numerous therapeutic
Table 1 Antimycobacterial, cytotoxic and anti-infective activities of commercially available 2-arylpropanoic acids (1–9)
MIC values against Mycobacterium (mg/L)
MIC values
against M
neoaurum in
Sauton’s agar
(mg/L)
M tuberculosis
H37Rv
M bovis
BCG M aurum M neoaurum pH=5.8 pH=7.0
Cytotoxicity
GIC50 (mg/L)
RAW264.7
Selectivity
index SI
(GIC50/
MIC)
MIC values (mg/L)
against M aurum
grown inside
RAW264.7
1 75 90 65 65 20 200 1000 13.3 100
2 90 >100 >100 >100 50 >200 1000 11.1 >100
3 100 >100 100 >100 20 200 1000 10 100
4 >100 >100 >100 >100 65 >200 1000 <10 >100
5 90 70 70 65 20 70 1000 11.1 >100
6 >100 >100 90 >100 50 >200 1000 <10 >100
7 40 65 40 40 20 40 1000 25 390
8 70 Nd Nd Nd Nd Nd 1000 14.3 Nd
9 >100 Nd Nd Nd Nd Nd 1000 <10 Nd
RIF 0.05 0.05 0.1 1 0.4 0.4 700 60 000 0.4
INH 0.05 0.1 0.4 2 0.4 1.6 3000 14 000 0.4
Nd, not determined.
INH, isoniazid; MIC, minimum inhibitory concentration; RIF, rifampin.
Table 2 Antitubercular activity and selectivity of synthetic
IBP derivatives (10–16)
MIC values against
Mycobacterium (mg/L)
M tuberculosis
H37RV
M bovis
BCG
Cytotoxicity
GIC50 (mg/L)
RAW264.7
Selectivity
index SI
(GIC50 /MIC)
10 >100 >100 750 <7.5
11 >100 100 325 <3.25
12 40 60 100 2.5
13 90 80 200 2.2
14 >100 >100 Nd Nd
15 30 50 400 13.3
16 40 >100 250 6.25
IBP, ibuprofen; MIC, minimum inhibitory concentration; Nd, not
determined.
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applications, acting as analgesics and anti-inﬂammatories
but also for treating neurodegenerative diseases and
cancer.20–22 The classical molecular targets of these
drugs are the two isoforms of cyclooxygenase (COX1
and COX2), which catalyse the transformation of arachi-
donic acid into the prostaglandins, which are essential
molecules mediating the inﬂammatory response. The
2-arylpropanoic acids have been reported to inhibit dif-
ferent enzymes and receptors, namely COX1 and
COX2, the subunits of the secretase receptor γ, the sub-
units of the peroxisome proliferator-activated receptor γ,
the nuclear factor κ and the Rho-GTPase.23 M tubercu-
losis H37Rv proteins that are homologous to the human
targets were dissected by using a basic local alignment
search tool (BLAST) of the NCBI online website, from
the amino acid sequence of the human proteins. The
analysis was extended to other sequenced mycobacterial
and non-mycobacterial organisms (table 5). For most of
the human targets of the 2-arylpropanoic acids, no sig-
niﬁcant sequence-homologue proteins were found in M
tuberculosis; however, for the human Rho-GTPase, a
mycobacterial homologue with a high level of similarity
(E value 10−5) was found (see online supplementary
ﬁgure S2). This protein, known as Rv2839c, has been
hypothetically annotated as a translation initiation factor
IF-2 (infB), being classiﬁed as an essential component
of protein synthesis initiation.24 A homologue of the
human Rho-GTPase was also identiﬁed in Mycobacterium
leprae, suggesting that it performs an essential task, and
therefore has been conserved through the genomic
decay of this pathogen. This homologue protein was also
detected in M smegmatis; however, it was not present in
either S aureus or E coli when a comparative genomic
analysis was performed. Moreover, a signiﬁcant homo-
logue of the COX1 and COX2 human enzymes was
identiﬁed only in the fast-growing M smegmatis (table 5),
a strain not inhibited by the 2-arylpropanoic acids,
ruling out that a COX-related protein might be inhib-
ited in mycobacteria.
DISCUSSION
Until now, the SPOTi assay has been used successfully to
identify hits with antimycobacterial activity derived from
natural and synthetic sources since 2004.5–7 We describe
here the automation and miniaturisation upgrade of the
SPOTi assay. In addition, the use of the SPOTi assay has
now been extended to other bacterial pathogens includ-
ing Gram-positive and Gram-negative species. The
HT-SPOTi assay has also been performed successfully
using a dilution of fungal cultures for determining MICs
of antifungal compounds (unpublished results).
HT-SPOTi synergism or antagonism assays have been
performed using a checkerboard distribution. By exten-
sion to the synergism/antagonism experiment, the possi-
bility of rescue of bacterial growth in the presence or
absence of certain medium components (such as
carbon sources, metals, amino acids, proteins and
others) can also be analysed, giving insight into the
mechanism of action of a particular growth inhibitor.
Furthermore, the use of a 96-well SPOTi assay enabled
the screening of large libraries available from different
existing collections retrospectively. Ultimately, as pheno-
typic screens have been successful tools for discovering
potent antibacterial drugs, the HT-SPOTi methodology
has the potential to identify new antimicrobial molecules
with clinical relevance.
Table 4 MIC values of selected 2-arylpropanoic acids (1, 7 and 15) and first-line anti-TB drugs using different bacterial
dilutions against exponential-phase (Log) and stationary-phase (Sta) Mycobacterium bovis BCG cultures
MIC values against M bovis BCG (mg/L)
Dilution Neat 10
-1 10-2 10-3
Physiological state Log Sta Log Sta Log Sta Log Sta
1 >100 >100 100 >100 80 100 80 80
7 80 >100 60 80 60 80 40 40
15 100 >100 100 100 60 60 60 60
INH 0.05 >10 0.05 >10 0.05 >10 0.05 >10
RIF 0.05 >10 0.01 10 0.01 10 0.01 1
EMB 10 >10 5 >10 5 >10 5 >10
EMB, ethambutol; INH, isoniazid; MIC, minimum inhibitory concentration; RIF, rifampin.
Table 3 MIC values of selected 2-arylpropanoic acids
(1, 7 and 15) against clinical Mycobacterium tuberculosis
multidrug resistant strains 11 : 139, 11 : 169 and 11 : 368
MIC values against MDR M tuberculosis
clinical isolates (mg/L)
11 : 139 11 : 169 11 : 368
1 50 50 30
7 40 50 20
15 50 40 40
INH 5 10 5
RIF 5 >25 25
EMB 20 10 5
STR 5 >25 5
All the MDR-strains were susceptible to kanamycin, amikacin,
capreomycin and p-aminosalicylic acid.
EMB, ethambutol; INH, isoniazid; MIC, minimum inhibitory
concentration; PAS, p-aminosalicylic acid; RIF, rifampin.
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This assay possesses advantages over other classical
and modern whole-cell phenotypic methods. Being an
agar-based method, contamination can be easily moni-
tored, resulting in more rigorous quality control in the
early stages of hit identiﬁcation. In addition, hydropho-
bic compounds are evenly distributed in the warm agar
(∼ 50°C) and on solidiﬁcation, the lower mobility
reduces the chances of aggregation, whereas lipophilic
compounds tend to precipitate in liquid-based methods
or do not diffuse well on the polar media used in the
zone of inhibition assays. Some natural products are
often coloured and thus can interfere with the ﬁnal
colorimetric read-out when using viability indicator
dyes (eg, methyl thiazolyl tetrazolium or resazurin/
Alamar Blue). Additionally, some compounds, such as
the ﬂavonoids, possess antioxidant properties, are con-
jugated and can reduce the oxidised dyes used in the
colorimetric assays, resulting in false positives.25 26 The
HT-SPOTi assay also has the potential to be employed
for the determination of DST of clinical isolates. As
shown in ﬁgure 1B, the multidrug-resistant EMRSA-16
strain was clearly differentiated from the susceptible
staphylococcal strain. The simplicity of the SPOTi
method makes it useful in a basic diagnostic laboratory.
We consider that the application of the HT-SPOTi assay
in DST would contribute to the control of bacterial
resistance, especially in rural areas where access to
sophisticated medical equipment (such as the mycobac-
terial growth indicator tube or the GeneXpert MTB/
RIF) is often lacking. The prepared plates with antibio-
tics could be shipped to distant locations and then
spotted with bacterial cultures in the local clinical
microbiology laboratory. In this way, phenotypic exam-
ination of TB drug susceptibility could be diagnosed
without the need for specialised instruments or expen-
sive consumables.
From the three most widely used OTC analgesics (para-
cetamol, aspirin and IBP), IBP showed the highest activity
against M bovis BCG. Aspirin was inhibitory at a concen-
tration of 250 mg/L, while IBP completely inhibited the
growth at 100 mg/L. Both aspirin and IBP have been
reported to exert in vivo synergistic effects with PZA in a
murine model of TB infection, being able to reduce by
more than 1 logarithmic unit the numbers of CFU with a
dose of 20 mg/kg compared with treatment with PZA
alone at 150 mg/kg.17 However, both compounds were
ineffective on their own, even at the highest dose tested
of 40 mg/kg. In a study on mice feeding with the highest
dose of IBP (1.36 g/kg diet), the maximal IBP plasma
concentration attained was around 20 mg/L27; however,
in humans, a high dose of 20–30 mg/kg achieved a
plasma concentration of 66–72 mg/L.28
Table 5 Putative potential molecular targets of the 2-arylpropanoic class in Mycobacterium tuberculosis based on homology
of the human reported targets
IBP/
2-arylpropanoic
acid molecular
target in
humans
Function in
humans
Homologues in
Mycobacterium
tuberculosis
H37Rv
Function in
Mycobacterium
tuberculosis
Homologues in
Mycobacterium
leprae
Homologues in
Mycobacterium
smegmatis
COX-1 Cyclooxygenase 1 No – No MS6324
(Evalue 10
-19)
COX-2 Cyclooxygenase 2 No – No MS6324
(Evalue 10
-19)
Presenilin-1 Trans-membrane
γ-secretasesubunit
No – No No
APH-1A γ-Secretase subunit
1A
No – No No
PEN-2 γ-Secretase subunit No – No No
NF-κB Nuclear factor κ
enhancer of
activated B cells
No – No No
APH-1B γ-Secretase subunit
1B
Rv2276
(Evalue 0.0013)
Cytochrome P450–121
CYP121
No No
Nicastrin γ-Secretase subunit Rv3411c
(Evalue 0.019)
Inosine-5-monophosphate
dehydrogenase guaB2
No No
PPARG-1/2 Peroxisome
proliferator
activated-receptor γ
Rv3146
(Evalue 0.007)
NADH-ubiquinone
dehydrogenase subunit B
No MS2062
(Evalue0.007)
RHO-GTPase Rho GTPase Rv2839c
(Evalue 10
-5)
Translation initiation factor
IF-2
ML1556
(Evalue 0.005)
MS0758
(Evalue 0.006)
This table shows the homologous proteins found in mycobacterial organisms that share sequence similarity with recorded human targets of
ibuprofen and other 2-arylpropanoic acids.
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The maximum human daily dose of IBP is 3200 mg,
and serious toxic effects appear with doses higher than
200–400 mg/kg.29 30 IBP shows strong binding to plasma
albumin and low binding to tissue proteins such as actin;
as a consequence, IBP has a low volume of distribution of
around 0.1–0.2 L/kg. IBP is incorporated into hybrid
lipids, particularly modiﬁed triglycerides, and this effect
actually enhances accumulation of IBP into adipose
tissue.31 In addition, IBP displays immunomodulatory
effects, being able to decrease the levels of inducible
nitric oxide synthase32 and the release of tumour nuclear
factor α and interleukin 1β in human mononuclear
cells.33 These processes are of crucial signiﬁcance in
dealing with intracellular pathogens and speciﬁcally with
M tuberculosis.34 35 It is therefore possible that the admin-
istration of IBP concomitant with current anti-TB therapy
could decrease the mycobacterial populations inside TB
patients; an effect which has yet to be measured.
Carprofen (7) was by far the most potent
2-arylpropanoic acid against both M tuberculosis H37Rv
and M bovis BCG with an MIC value of 40 mg/l. This
drug was less active against the fast-growing mycobacteria
M aurum and M neoaurum (MIC ∼ 70 mg/l) and inactive
against M smegmatis (MIC >100 mg/L) or the acid-fast
bacillus R equi RHA1. The speciﬁcity against the M tuber-
culosis complex perhaps indicates an underlying bio-
logical mechanism that uniquely targets an essential
protein of the M tuberculosis complex while having
less afﬁnity for the same macromolecule in other
bacterial species. Among the commercially available
2-arylpropanoic acids, carprofen had the better selectivity
proﬁle achieving SI values of 25, conﬁrming its high anti-
tubercular speciﬁcity.
In animals, carprofen (7) is widely used for treating
pain and inﬂammation.36 It has high plasma concentra-
tion in cats, achieving levels from 25 to 50 mg/L after
administration of a low dose of 4 mg/kg during the ﬁrst
7 h.37 However, in dogs, the plasma levels were inferior
(between 2 and 15 mg/L) for the same dose.38 In
humans, the plasma levels after a single oral dose of
150 mg rose to 10 mg/L during the ﬁrst 5 h after admin-
istration.39 The half lethal dose (LD50) of carprofen in
mice is 282 mg/kg and in rats it is 149 mg/kg.
Carprofen has been used in humans at doses of up to
600 mg/kg, being well tolerated.40 The results obtained
in this work and the cited data suggest that carprofen or
a lower-toxicity carprofen derivative (such as the recently
developed reduced-toxicity IBP derivative)41 could be
developed as a useful anti-TB drug.
The synthetic derivatives obtained from IBP revealed
that the free carboxylic acid group was essential for its
mycobacterial growth inhibitory properties. The forma-
tion of either esters or amides was detrimental to in
vitro activity. It was also noticed that the cytotoxicity of
the amides and particularly of the esters increased dra-
matically compared with the free carboxylic acids.
Therefore, in order to increase the potency of the
2-arylpropanoic acid class, any potential chemical
modiﬁcation should ideally be carried out on the aryl
ring. Following this premise, nitration of IBP was envi-
saged as this substitution can be easily modiﬁed to gen-
erate other groups such as anilines and phenols.
3,5-Dinitro-IBP was more active than the parent com-
pound, showing an MIC value around half that of IBP,
while maintaining its relative cytotoxicity, as the SI had
the same value (SI ∼13) for both compounds.
The growth curves of the three selected
2-arylpropanoic acids further conﬁrmed that carprofen
(7) was the most active growth inhibitor of slow-growing
mycobacteria. In both experimental settings, either
when the drugs were added at the time of inoculation
or when the drugs were added in the early-exponential
phase of growth, 7 (at 2×MIC concentration) completely
prevented (or arrested) the growth of M bovis BCG. The
CFU analysis demonstrated that this speciﬁc inhibitor
was highly inhibitory when added in the lag phase of
bacterial growth but did not affect bacterial viability
when included at the exponential phase. This density-
dependent antibacterial effect has been previously
observed for omeprazole against Helicobacter pylori, being
bactericidal when incubated from the start of the
culture, but being bacteriostatic if added to
the exponential-phase culture.42 It remains possible that
several antibacterial drugs show this behaviour, a phe-
nomenon which remains underexplored.
IBP (1), carprofen (7) and 3,5-dinitro-IBP (15) were
all active against MDR clinical isolates. The members of
the arylpropanoic class seem to inhibit the growth of
slow-growing mycobacterial species by not interacting
with the target proteins of ﬁrst-line anti-TB drugs,
namely InhA (or KasA), RpoB and EmbC. More interest-
ingly, the 2-arylpropanoic acids were active against the
100-day old stationary M bovis BCG culture, having the
same MIC values as those obtained against the
exponential-phase bacilli. However, the ﬁrst-line anti-TB
drugs INH and RIF increased their MIC values more
than 100-fold against the stationary-phase bacteria com-
pared with exponential-phase cultures. The tolerance to
INH and RIF of this physiologically dormant state of
mycobacteria has been repeatedly reported using differ-
ent dormancy models.43–45 These results suggest that the
2-arylpropanoic acids target pathways associated with
fundamental biological processes required in both the
high and low metabolic states of intracellularly surviving
mycobacterial pathogens.
The comparative bioinformatic approach used to
propose potential targets of the 2-arylpropanoic class in M
tuberculosis suggested the translation initiation factor IF-2
(Rv2839c) protein (InfB) as a possible endogenous target
in mycobacteria. The InfB protein forms a complex with
the ﬁrst tRNA, which interacts speciﬁcally with
N-formylmethionine, the ﬁrst amino acid to be incorpo-
rated in nascent proteins.46 Therefore, InfB plays a crucial
role in protein synthesis. The possibility that the 2-
arylpropanoic NSAIDs target protein synthesis is in agree-
ment with the inhibition of both exponential and
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stationary-phase M bovis BCG cells, as in the physiological
stages of low metabolic activity, cells still need to synthesise
proteins, a process which is deemed to occur at reduced
rates compared with exponential-phase bacilli.47 48
The NSAID oxyphenbutazone has received recent
attention for its activity against non-replicating
M tuberculosis,14 and therefore it is possible that
NSAIDs share a common mechanism of action against
the mycobacterial stages of low metabolic activity, a
chemobiological feature that could be exploited for
the introduction of a new generation of drugs against
latent TB infection.
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